Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Global Hemifacial Spasm Market - Industry Trends and Forecast to 2028

Pharmaceutical | Upcoming Report | Feb 2021 | Global | 350 Pages | No of Tables: 220 | No of Figures: 60

Report Description

Global Hemifacial Spasm Market, By Treatment (Oral Medication, Botulinum Toxin And Surgery), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: Global Hemifacial Spasm Market

Hemifacial spasm market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.00% in the above-mentioned research forecast period. Increase in geriatric population and easy availability of diagnostic tool for disease characterization and to recognize the disease severity among others.

Easy availability of anticonvulsant drugs and increasing incidence of craniofacial tremor, facial chorea along with rising unmet patients need also boost up the market growth. Moreover, increase in partnership and collaboration among market players, presence of reimbursement and increasing research and development for innovation of novel treatment approach act as opportunity for the market growth. But, lack of skilled professionals to carry out efficient diagnosis, high cost of treatment, side effects associated with botulinum toxin and strict regulations may hamper the global hemifacial spasm market.

Hemifacial spasm, a neuromuscular disorder recognized by the frequent involuntary contractions of the muscles present on one side of the face. This disorder affects both men as well as women, however middle aged or elderly women are more likely to affected. The most common symptoms associated with hemifacial spasm include intermittent twitching of eyelid muscle that leads to forced closure of eyes. Gradually the spasm progress towards lower face that result pulling of facial muscles from one side.  Hemifacial spasm can be caused due to tumor or facial nerve injury. Moreover as per the observations of doctors hemifacial spasm occurs due to pressing of blood vessel pressing the facial nerve at the place where its exits the brain stem. The treatment of hemifacial spams includes the use of anticonvulsant drugs, muscle relaxants, physical therapy, combinational therapy, transcutaneous electrical nerve stimulation therapy among others. Among several types of therapies available botulinum toxin therapy is widely accepted therapy indicated for treatment of hemifacial spasm. Moreover in severe cases invasive treatment approaches are also adopted which involves surgical treatment. The surgical treatment used for hemifacial spams includes microvascular decompression among others which relaxes the pressure over the facial nerves.

Hemifacial spasm is one of the rare conditions and its estimated prevalence worldwide reported to be 14.5 cases per 100,000 women and 7.4 among every 100,000 men. The hemifacial spasm are most likely to affect geriatric population of 40 years and above that. As geriatric population increasing at a rapid rate throughout the world, it can lead to rising number of hemifacial spams cases which ultimately demands effective treatment approaches hence expected to provide market with the lucrative growth.

This hemifacial spasm market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Hemifacial Spasm Market Scope and Market Size

Hemifacial spasm market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of treatment, the hemifacial spasm market is segmented into oral medication, botulinum toxin and surgery. Oral medication is further sub- segmented into carbamazepine, gabapentin, benzodiazepines (clonazepam), anticholinergics, baclofen, haloperidol, among others. Botulinum toxin is sub-segmented into type A and type B.
  • On the basis of route of administration, the hemifacial spasm market is segmented into oral, parenteral, others.
  • On the basis of end-users, the hemifacial spasm market is segmented into clinics, hospitals, homecare, others.
  • On the basis of distribution channel, the hemifacial spasm market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, others. 

Hemifacial spasm Market Country Level Analysis

Hemifacial spasm market is analysed and market size information is provided by country, type, treatment, end-users and distribution channel as referenced above.

The countries covered in the hemifacial spasm market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to rising number of geriatric patients and well-established health care facilities. Europe accounts the second largest market share due to easy availability of anticonvulsant drugs and growing awareness towards neurological disorders. Asia-Pacific is expected to account for the largest market share over coming years for the hemifacial spasm market due to increasing demand of effective therapies and rapidly changing health care infrastructure along with easy availability of drugs.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Hemifacial spasm market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Hemifacial Spasm Market Share Analysis

Hemifacial spasm market competitive landscape provides details by competitor, details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to hemifacial spasm market.

The major players covered in the hemifacial spasm market are Pfizer Inc., Mylan N.V., F. Hoffmann-La Roche AG, Novartis AG, Allergan plc., Piramal Critical Care, Inc., Apotex Inc., Shire Plc, and Validus Pharmaceuticals LLC., DAEWOONG PHARMACEUTICAL  CO.,LTD., Evolus, Inc., USWM, LLC., Revance, Cyclo Therapeutics, Inc., Medytox, Hughs, Merz Pharma,  Ipsen Pharma, HUGEL, Inc., Eisai Co., Ltd.,  AlphaVax among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.


SKU-

Table of Content

Please fill in the below form for detailed Table of Content

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Table

Please fill in the below form for detailed List of Table

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Figure

Please fill in the below form for detailed List of Figure

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

View Infographics

Please fill in the below form for detailed Infographics

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country
CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19